Statistics & PMx

(M-040) Novel endpoints based on tumor growth dynamics – A comprehensive simulation study with retrospective validation

(M-055) Immune Correlates of Protection against Respiratory Syncytial Virus Infection and an Application to Model-Informed Vaccine Development for an internal compound: a Model-Based Meta-Analysis

(M-076) Methodology of the Exposure-Response (E-R) Analysis of Linvoseltamab in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)

(M-087) Model Platform to Predict Long-Term Clinical Outcome for Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

(M-090) A Novel Approach to Capturing the Dynamics of Nontarget and New Tumors in Mechanistic Models of Progression-Free Survival

(M-091) Fully Bayesian Covariate Selection in Population Pharmacokinetics and Pharmacodynamics Models Using Regularized Horseshoe Priors

(T-024) A Bayesian Approach to Item Response Theory Modeling for Exposure-Response Relationships in Stan

(T-042) Use of Model-informed Drug Development and Natural History Data to Inform the Development of Iluzanebart in ALSP: A Neurological Rare Disease

(T-063) Advancing Modeling of Hematologic Safety using a Semi-mechanistic Multivariate PK/PD Approach: Application to the ATR Inhibitor Tuvusertib in Early Phase Oncology Development

(T-066) A Novel Concentration-Based Time-Imputation Algorithm for Large Cohort Studies Missing Time-After-Dose Data for Stored Samples

(T-078) A Bayesian Semi-Mechanistic Dose-Finding Design for Phase I Drug Combination Trials in Oncology

(T-112) Application of Machine Learning Methods to Predict Risk of Adverse Events in Clinical Trials

(T-135) Potential Bias Evaluation of Conventional Exposure-Response Analysis Methods: A Small Molecule Cancer Drug Example

(W-003) Leveraging Machine Learning and Real-World Data: Time-to-Event Analysis of COVID-19 Patients Using Electronic Health Records

(W-012) Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions

(W-032) Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis.

(W-041) Inferring HIV rebound timing from a noisy biomarker

(W-069) Exploring Appropriate Prior Distributions for Covariance Matrix Estimation in Bayesian Population Pharmacokinetic Analysis

(W-085) The Influence of Systematic and Technical Errors on Population Pharmacokinetic / Pharmacodynamic Model Parameters: Nonlinear Mixed-Effect Approach

(W-133) Losing the Forest: Causal Shapley Additive Explanations for Interpretation of Population-Pharmacokinetic models

(W-134) Causal directed acyclic graph (DAG) application in exposure-response analyses

(W-136) Gompertz Cure Rate Survival Models with Stan and Brms

(W-139) Design and evaluation of a novel decision metric for estimating Phase 1 Maximum Tolerated Dose